Drug Profile


Alternative Names: Cytotropic heterogeneous molecular lipids

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Glory Pharmaceuticals
  • Developer Glory Pharmaceuticals; National Cancer Institute (USA)
  • Class Antineoplastics; Saturated fatty acids; Triterpenes; Unsaturated fatty acids; Vitamins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Cancer
  • Phase II Liver cancer

Most Recent Events

  • 11 Oct 2018 CHML is still in clinical trials for Cancer (Glory Pharmaceuticals website, October 2018)
  • 27 Aug 2015 Development in Cancer is ongoing in USA
  • 27 Aug 2015 The process for obtaining manufacturing approval in China is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top